ILICOGENIX
A Quantum Chemical Biology Company
Silicogenix is making the entire human proteome druggable.
Period.
Only
2%
of the human proteome is accessible to drugs
Imagine the diseases we could cure if we could target a larger portion of the proteome.
We are pioneering the most comprehensive small molecule library built to date to target the majority of the human proteome. We want to bring novel, first-in-class medicines to the market while addressing crucial unmet needs.
We are starting with a focus on rare cancers.
Technology
Our AI-driven, classical+quantum computational chemistry and chemical biology based tools are built to answer two specific questions: a) solving the proteome druggability problem at scale; & b) reducing barriers to entry into preclinical development
Design, don't screen!
Traditional pipeline
(bottom-up)
-
Agnostic: To protein types
-
Ultra-fast: Novel small molecules designed in <48hrs
-
Ultra-high-throughput: Thousands of designs
-
Parallel: Design for multiple targets simultaneously
-
Drug-focused: Molecules pre-optimized for favorable development properties like good PK/PD, low tox etc.
By focusing on discovery chemistry, we can enable concept to pre-clinical transition in as early as 2 months!
We can leverage targeting gains to rapidly launch pre-clinical programs
Silicogenix's pipeline
(top-down)
What's new at SGX
-
SGX establishes a Technical Advisory Panel (TAB) with Subbu Iyer, Karan Syal, Tim Sears and Vishv Jeet as members help guide deep dives into computational and engineering tool development (March 2025)
-
Tim Sears, Karan Syal and Alok Singhania to join SGX as Advisors starting March 2025!
-
SGX debuts its first CADDE-designed "lead-series" with known precursors from a CRO Jan 3, 2025! Getting ready for our first pre-clinical program in CLL!
-
SGX welcomes 3 new engineers starting November 1, 2024! Welcome aboard Juan, JD, Paulina!
-
SGX held its first strategy offsite on September 11, 2024 at VC Nest in Palo Alto! Many thanks to Lochan Alagh for making the space available.
-
SGX welcomes Ryan Flynn, Ph.D. (Harvard, Savant Ventures) to the team as Strategic Advisor
-
SGX welcomes Kevin Lynch, Ph.D. (ex CBO Recursion, Notable; ex VP Abbott, Abbvie, Vir) to the team.
Partners
Startup Programs
Our Story
Do you really need millions of dollars worth of computational infrastructure to demonstrate the power of AI for drug development?
We don't think so....
Could we take a small but extremely talented team, clever scientific thinking, off-the-shelf components and some chutzpah to legitimately harness the power of AI for drug discovery?
We show we absolutely can: with a very small team, two off-the-shelf servers that cost less than what you would spend on a vacation, and a number of novel computational chemistry tools and frameworks, we have built small molecules that are drug like, biologically active, inhibit in a dose-dependent-fashion and are chemically novel. Our entire process from molecule design to activity validation takes only about 3 months. In fact, with just pre-seed funding, we are getting ready to put molecules into pre-clinical development. THAT IS THE TRUE POWER OF AI!
Our Vision
Many Molecules, Many Targets, Many Cures
TM
Very often in Pharma, scientists scramble to identify the one key protein that will be bring about disease cure or remission. But every disease is a breakdown in process, with many players (proteins, pathways) involved that become dysfunctional. At SGX, we see and treat disease as a process, with the possibility of many points of intervention, rather than chasing a single key. To this end, the SGX team is attempting a big feat- making the entire human proteome druggable, so we can effectively target not just a single protein but entire pathways as well, in various ways including combinations. Many molecules for many targets, leading to many cures!
Team
Shailesh Date, Ph.D.
Co-Founder & CEO
CEO, LRC Systems
Assoc. Adj. Professor, UCSF
Comp. Bio, Biophysics, Inf. Diseases
Jose Jaramillo, Ph.D.
Co-Founder & CTO
Sr. Scientist & Head of High Perf. Computing Research Ctr, LRC
Prof. of Computer Engineering, UTP
Former Fulbright Fellow (@Purdue)
Photonics, Quantum Computing
Dan Serna, MS
Sr. Engineer
AI
Jose Duarte
Engineer & TechOps Manager
Math, AI, Autonomous agents
Paulina Escobar
Computational Chemist
Chemistry, Mol. Dynamics
Juan Aguirre
Engineer
AI, Databases
Fred Castaneda
Engineer
AI, Computational Chemistry
Andres Giraldo, MS
Engineer & Developer
Quantum Computing
Scientific Advisory Board (SAB)
Andrew Calabrese, Ph.D.
Member, SAB
Founding CSO, Animol Discovery;
Founder Revagenix
Ex. Pfizer, Celegene, AgriMetis
Lee Swem, Ph.D.
Member, SAB
CDO @ Kanvas Bio
Ex CSO FedBio & Achaogen,
Ex. Genentech
Subramanian Iyer, Ph.D.
Member, SAB
Member, TAB
SVP of AI, QXO
Ex Head of AI @Target
Ex. Goldman Sachs, Google
Technical Advisory Board (TAB)
Tim Sears, Ph.D.
Member, TAB
Head of Software Applications, Groq
Ex. Target, Goldman Sachs, Morgan Stanley, Lehman Brothers
Karan Syal, Ph.D.
Member, TAB
Head, AI Partnerships, Reveal Health
Founder & CEO, iVIzz (exited)
Ex. Genentech
Vishv Jeet, Ph.D.
Member, TAB
Quantitative Trading Specialist
Founder, Mindtapp.app
Ex VP Research, PGIM
Ex. Assoc. Dir, MSCI Private Capital
Business Development
Kevin Lynch, Ph.D.
Strategic Advisor
Ex CBO Recursion, Notable
Ex VP Abbvie, Vir
Ryan Flynn, M.D. Ph.D.
Strategic Advisor
Asst. Professor, Harvard
Savantus Ventures (not as investor)
Alok Singhania
Partner Gridscape
Ex. CEO/Co-Founder/President Blindfish, Mobifusion, Info Objects
Josh Siedenfeld, JD
Legal Counsel
Cooley
Dana White, MBA
Finance Director
Engineroom
(Note: SGX appointment not through Engineroom)
Other Advisors
Nilesh Rajadhyax, MBA
COO Medquest,
Ex. CEO GEDC,
Ex. McKinsey
Vibhav Garg, MS
Pinterest; Ex Twitter,
Facebook (Meta)
Zack Abbott, Ph.D.
CEO, Zbiotics
Ricky Ghoshal, MBA
Evercore
Neil Cohen, MBA
Hexagon Federal
Don Oppenheim, MBA
COO (Retired), Meyers Nave;
Partner (Retired), Altman Weil
Pipeline
Our initial focus is on Oncology and Immunology. SGX is currently developing small molecule inhibitors against multiple targets in Chronic Lymphocytic Leukemia (CLL), which serves as our development prototype. We are expanding to rare oncology indications as each step is validated.
Target
Design/Discovery (Validation)
Early Development
(Optimization)
Pre-Clinical
(IND-Enabling)
IND
CLL (Primary)
CLL (Secondary)
First scaffolds generated
Rare Cancer 1
(Planned)
Rare Cancer 2
(Planned)
New programs driven by degree of unmet need
The Silicogenix team is constantly evaluating business opportunities in various disease areas (even outside of Oncology) to better understand Pharma focus, M&A activity and unmet need. The team uses this information to design new programs to quickly develop products that are likely to impact areas with greatest unmet needs, such as rare cancers. Our technology allows us to rapidly develop new molecules and test a number of unique, patentable scaffolds that can be pushed in pre-clinical development within months. This allows us to launch new programs at an unprecedented speed.
Contact Us
Mailing Address
655 Oak Grove Ave. #1417
Menlo Park, CA 94025
Office
1336 N Carolan Ave #206
Burlingame, CA 94010
Phone
(415) 570-9067
Please send an email to business-manager (at our domain)
The Magicians!
_edited.png)